Eton Pharmaceuticals Inc (ETON)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $1.84B
Last updated: Nov 17, 2026 at 11:05 AM ET
Eton Pharmaceuticals Inc (ETON) Financials: Revenue, Profit and Cash Flow
Eton Pharmaceuticals reported revenue of $79.95M for the fiscal year ended Dec 31, 2025, up 104.9% from the year before. That year, net income was -$4.60M with a net margin of -5.8%, operating cash flow was $10.52M and free cash flow was $10.19M. The quarter ended Sep 30, 2026 had revenue of $57.92M and net income of $35.25M.
Revenue and Margins
The operating margin was -1.1% in the fiscal year ended Dec 2025, the highest of the 5 years shown with an operating margin. Over the 6 years to Dec 2025, revenue grew from $959.00K, a compound annual rate of 109.0%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $79.95M | +104.9% | 53.5% | -1.1% | -5.8% |
| Dec 2024 | $39.01M | +23.3% | 60.0% | -6.7% | -9.8% |
| Dec 2023 | $31.64M | +48.9% | 66.6% | -3.8% | -3.0% |
| Dec 2022 | $21.25M | -2.7% | 67.4% | -38.9% | -42.4% |
| Dec 2021 | $21.83M | +55879.5% | 87.1% | -6.8% | -9.0% |
| Dec 2020 | $39.00K | -95.9% | -1017.9% | -69515.4% | -71717.9% |
| Dec 2019 | $959.00K | N/A | 52.8% | -1939.6% | -1910.3% |
| Dec 2018 | $0 | N/A | N/A | N/A | N/A |
| Dec 2017 | $0 | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, net income turned positive after a loss in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $79.95M | $39.01M | $31.64M | $21.25M | $21.83M | $39.00K | $959.00K | $0 | $0 |
| Cost of revenue | $37.21M | $15.60M | $10.58M | $6.93M | $2.83M | $436.00K | $453.00K | $0 | $13.00K |
| Gross profit | $42.74M | $23.41M | $21.06M | $14.32M | $19.00M | -$397.00K | $506.00K | $0 | -$13.00K |
| Research and development | $7.76M | $3.25M | $3.32M | $4.00M | $6.24M | $14.10M | $11.55M | $5.63M | $3.93M |
| Operating income | -$844.00K | -$2.60M | -$1.19M | -$8.26M | -$1.50M | -$27.11M | -$18.60M | -$10.32M | -$7.15M |
| Net income | -$4.60M | -$3.82M | -$936.00K | -$9.02M | -$1.96M | -$27.97M | -$18.32M | -$12.74M | -$7.16M |
| EBITDA | $182.00K | -$1.55M | $329.00K | -$7.12M | N/A | N/A | -$17.86M | N/A | -$7.14M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $57.92M | $37.59M | $24.27M | $21.28M | $22.46M | $18.93M | $17.28M | $11.65M | $10.32M | $9.07M | $7.97M | $7.31M |
| Gross profit | $44.30M | $25.41M | $14.73M | $13.10M | $7.86M | $11.92M | $9.86M | $6.48M | $6.30M | $5.63M | $5.01M | $3.63M |
| Operating income | $23.01M | $12.79M | $2.41M | $2.46M | -$1.36M | -$1.48M | -$470.00K | $629.00K | $509.00K | -$2.94M | -$800.00K | -$1.99M |
| Net income | $35.25M | $11.58M | $1.55M | $1.48M | -$1.93M | -$2.58M | -$1.57M | -$598.00K | $627.00K | -$3.04M | -$811.00K | -$2.26M |
Balance Sheet
As of Dec 2025, total debt of $30.56M exceeded cash and equivalents by $4.62M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | $92.11M | $76.12M | $31.74M | $25.03M | $27.46M | $26.32M | $17.07M | $28.33M | $13.44M |
| Current assets | $60.58M | $41.02M | $26.84M | $20.00M | $23.60M | $24.70M | $15.01M | $27.50M | $13.29M |
| Cash and equivalents | $25.94M | $14.94M | $21.39M | $16.30M | $14.41M | $21.30M | $12.07M | $26.73M | $13.16M |
| Total liabilities | $65.96M | $51.70M | $16.26M | $11.95M | $9.84M | $10.66M | $6.52M | $2.02M | $1.31M |
| Short-term debt | $8.79M | $0 | $5.38M | $1.03M | $1.42M | $0 | $0 | $0 | $0 |
| Long-term debt | $21.77M | $29.81M | $0 | $5.38M | $5.26M | $6.76M | $4.54M | $0 | $0 |
| Shareholder equity | $26.15M | $24.43M | $15.48M | $13.08M | $17.63M | $15.66M | $10.55M | $26.30M | -$6.87M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $157.27M | $115.81M | $97.71M | $92.11M | $104.51M | $101.68M | $84.03M | $76.12M | $35.84M | $31.82M | $30.79M | $31.74M |
| Total liabilities | $70.35M | $69.22M | $67.09M | $65.96M | $81.38M | $77.72M | $59.58M | $51.70M | $19.86M | $18.36M | $15.30M | $16.26M |
| Cash and equivalents | $55.63M | $26.84M | $19.66M | $25.94M | $37.12M | $25.38M | $17.42M | $14.94M | $20.26M | $17.69M | $16.66M | $21.39M |
| Shareholder equity | $86.92M | $46.59M | $30.61M | $26.15M | $23.13M | $23.96M | $24.45M | $24.43M | $15.98M | $13.46M | $15.49M | $15.48M |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 96.9% of operating cash flow.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $10.52M | $969.00K | $6.82M | $4.82M | -$4.72M | -$22.35M | -$18.03M | -$8.14M | -$4.72M |
| Capital expenditures | $333.00K | $26.00K | $0 | $38.00K | $9.00K | $50.00K | $1.10M | $236.00K | $130.00K |
| Free cash flow | $10.19M | $943.00K | $6.82M | $4.78M | -$4.73M | -$22.40M | -$19.12M | -$8.38M | -$4.85M |
| Dividends paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $1.05M | $0 |
| Investing cash flow | -$333.00K | -$40.01M | -$775.00K | -$2.79M | -$2.56M | -$50.00K | -$1.85M | -$236.00K | -$130.00K |
| Financing cash flow | $815.00K | $32.59M | -$957.00K | -$134.00K | $391.00K | $31.63M | $5.20M | $21.96M | $18.00M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $35.24M | $7.25M | $7.41M | -$11.55M | $12.03M | $7.96M | $2.09M | -$765.00K | $2.95M | $1.25M | -$2.47M | $387.00K |
| Capital expenditures | $13.00K | $5.00K | $75.00K | $49.00K | $284.00K | $0 | $0 | $12.00K | $1.87M | $0 | $14.00K | $775.00K |
| Free cash flow | $35.23M | $7.25M | $7.33M | -$11.60M | $11.74M | $7.96M | $2.09M | -$777.00K | $1.08M | $1.25M | -$2.49M | -$388.00K |
Frequently Asked Questions About ETON
What is Eton Pharmaceuticals' annual revenue?
Eton Pharmaceuticals reported revenue of $79.95M for the fiscal year ended Dec 31, 2025.
How fast is Eton Pharmaceuticals' revenue growing?
Revenue was up 104.9% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 55.5%.
Is Eton Pharmaceuticals profitable?
No. Eton Pharmaceuticals reported net income of -$4.60M for the fiscal year ended Dec 31, 2025, with a net margin of -5.8%.
How much free cash flow does ETON generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $10.52M minus capital expenditures of $333.00K produced free cash flow of $10.19M.
How much debt does Eton Pharmaceuticals have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $21.77M, short-term debt of $8.79M and cash and equivalents of $25.94M.
ETON pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors